Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 1
1963 1
1965 11
1966 21
1967 35
1968 45
1969 37
1970 41
1971 69
1972 38
1973 70
1974 51
1975 49
1976 49
1977 48
1978 39
1979 47
1980 46
1981 36
1982 55
1983 50
1984 57
1985 38
1986 66
1987 79
1988 99
1989 102
1990 146
1991 129
1992 163
1993 154
1994 233
1995 270
1996 300
1997 299
1998 270
1999 308
2000 361
2001 419
2002 457
2003 470
2004 628
2005 759
2006 821
2007 796
2008 804
2009 1009
2010 1161
2011 1199
2012 1293
2013 1328
2014 1382
2015 1654
2016 1632
2017 1695
2018 1824
2019 1335
2020 112
Text availability
Article attribute
Article type
Publication date

Search Results

22,456 results
Results by year
Filters applied: . Clear all
Page 1
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC).
Brahmer JR, Govindan R, Anders RA, Antonia SJ, Sagorsky S, Davies MJ, Dubinett SM, Ferris A, Gandhi L, Garon EB, Hellmann MD, Hirsch FR, Malik S, Neal JW, Papadimitrakopoulou VA, Rimm DL, Schwartz LH, Sepesi B, Yeap BY, Rizvi NA, Herbst RS. Brahmer JR, et al. J Immunother Cancer. 2018 Jul 17;6(1):75. doi: 10.1186/s40425-018-0382-2. J Immunother Cancer. 2018. PMID: 30012210 Free PMC article.
A systematic review of targeted agents for non-small cell lung cancer.
Vestergaard HH, Christensen MR, Lassen UN. Vestergaard HH, et al. Acta Oncol. 2018 Feb;57(2):176-186. doi: 10.1080/0284186X.2017.1404634. Epub 2017 Nov 25. Acta Oncol. 2018. PMID: 29172833 Review.
Durvalumab in cancer medicine: a comprehensive review.
Alvarez-Argote J, Dasanu CA. Alvarez-Argote J, et al. Expert Opin Biol Ther. 2019 Sep;19(9):927-935. doi: 10.1080/14712598.2019.1635115. Epub 2019 Jul 5. Expert Opin Biol Ther. 2019. PMID: 31272242 Review.
[Expert recommendations 2006 on the rationale for second-line therapy for non-small cell bronchial neoplasms].
Hilbe W, Aigner K, Dittrich C, Eckmayr J, Fiegl M, Flicker M, Forstner B, Greil R, Jamnig H, Krajnik G, Lang A, Mohn-Staudner A, Schinko H, Studnicka M, Pirker R, Ploner F, Rothmund J, Schiller L, Zabernigg A, Zöchbauer-Müller S. Hilbe W, et al. Wien Klin Wochenschr. 2007;119(7-8):259-66. doi: 10.1007/s00508-007-0792-5. Wien Klin Wochenschr. 2007. PMID: 17492355 Review. German. No abstract available.
Invited Commentary.
Kim J. Kim J. Ann Thorac Surg. 2016 Feb;101(2):540. doi: 10.1016/j.athoracsur.2015.09.065. Epub 2015 Nov 25. Ann Thorac Surg. 2016. PMID: 26627177 No abstract available.
Chemotherapy for Advanced Non-small Cell Lung Cancer.
Dietrich MF, Gerber DE. Dietrich MF, et al. Cancer Treat Res. 2016;170:119-49. doi: 10.1007/978-3-319-40389-2_6. Cancer Treat Res. 2016. PMID: 27535392 Review.
[Medical treatment of lung cancer].
Mellemgaard A, Andersen JL, Langer S. Mellemgaard A, et al. Ugeskr Laeger. 2018 Nov 12;180(46):V04180262. Ugeskr Laeger. 2018. PMID: 30417810 Danish.
[Research Advances in CIMAvax-EGF for Non-small-cell Lung Cancer].
Zhang JY, Zhu L, Yang HK, Chen F. Zhang JY, et al. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2018 Jun 28;40(3):411-414. doi: 10.3881/j.issn.1000-503X.2018.03.020. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2018. PMID: 29978802 Free article. Review. Chinese.
Using Immune Checkpoint Inhibitors in Lung Cancer.
Marrone KA, Brahmer JR. Marrone KA, et al. Oncology (Williston Park). 2016 Aug;30(8):713-21. Oncology (Williston Park). 2016. PMID: 27528240 Free article. Review.
22,456 results
Jump to page
Feedback